Cruising Through Change: The Auto-Finance Industry’s New Era Under Trump Unveiled — The Consumer Finance Podcast
2023 CRA Rule Repeal: Lessons to be Learned
Regulatory Rollback: Inside the CFPB’s FCRA Guidance Withdrawal — The Consumer Finance Podcast
Cruising Through Change: The Auto-Finance Industry’s New Era Under Trump Unveiled — Moving the Metal: The Auto Finance Podcast
DOL Restructures: OFCCP on the Chopping Block as Opinion Letters Expand - #WorkforceWednesday® - Employment Law This Week®
Compliance into the Weeds: Changes in FCPA Enforcement
Regulatory Rollback: Inside the CFPB's FCRA Guidance Withdrawal — FCRA Focus Podcast
10 For 10: Top Compliance Stories For the Week Ending June 7, 2025
Daily Compliance News: June 5, 2025, The Asset Cap Lifted Edition
Episode 371 -- DOJ's New Corporate Enforcement Program
LathamTECH in Focus: How Should Crypto Companies Be Thinking About New Laws?
Regulatory Rollback: Impact on Industry of CFPB's Withdrawal of Fair Lending and UDAAP Informal Guidance — The Consumer Finance Podcast
The LathamTECH Podcast — Where Digital Assets Slot Into a Shifting Fintech Regulatory Landscape: Insights From the US, UK, and EU
The fatal flaws in the 2023 CRA rule
Everything Compliance: Shout Outs and Rants - Episode 154
Daily Compliance News: May 16, 2025, The Ethics Nightmare Edition
New York State Restaurant Reservation Anti-Piracy Act Cracks Down on a "Leech Industry"
Consumer Finance Monitor Podcast Episode: The Impact of the Election on the FTC
Compliance Tip of the Day: Standing at the Turning Point
Federal Court Strikes Down FDA Rule on LDTs - Thought Leaders in Health Law®
As the Trump administration’s antitrust landscape continues to develop, companies should stay alert to key changes in merger filing requirements, remedy expectations, agency personnel, and more. The Federal Trade Commission...more
On March 12, 2025, the UK’s Competition and Markets Authority (CMA) launched a consultation on its approach to merger remedies, asking whether the authority should permit more complex remedies in Phase I investigations and...more